Unknown

Dataset Information

Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study.


ABSTRACT:

Background

Genetic risk factors for chemotherapy-induced peripheral neuropathy (CIPN), a major dose-limiting side-effect of paclitaxel, are not well understood.

Methods

We performed a genome-wide association study (GWAS) in 183 paclitaxel-treated patients to identify genetic loci associated with CIPN assessed via comprehensive neuropathy phenotyping tools (patient-reported, clinical and neurological grading scales). Bioinformatic analyses including pathway enrichment and polygenic risk score analysis were used to identify mechanistic pathways of interest.

Results

In total, 77% of the cohort were classified with CIPN (n = 139), with moderate/severe neuropathy in 36%. GWAS was undertaken separately for the three measures of CIPN. GWAS of patient-reported CIPN identified

SUBMITTER: Hooshmand K 

PROVIDER: S-EPMC9724416 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature